EPS for Obalon Therapeutics, Inc. (OBLN) Expected At $-0.48

February 13, 2018 - By Henry Gaston

 EPS for Obalon Therapeutics, Inc. (OBLN) Expected At $ 0.48

Analysts expect Obalon Therapeutics, Inc. (NASDAQ:OBLN) to report $-0.48 EPS on February, 22.They anticipate $0.03 EPS change or 5.88 % from last quarter’s $-0.51 EPS. After having $-0.55 EPS previously, Obalon Therapeutics, Inc.’s analysts see -12.73 % EPS growth. The stock decreased 3.67% or $0.16 during the last trading session, reaching $4.2. About 55,963 shares traded. Obalon Therapeutics, Inc. (NASDAQ:OBLN) has 0.00% since February 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Obalon Therapeutics, Inc. (NASDAQ:OBLN) Ratings Coverage

Among 2 analysts covering Obalon Therapeutics (NASDAQ:OBLN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Obalon Therapeutics had 2 analyst reports since October 31, 2016 according to SRatingsIntel. UBS initiated Obalon Therapeutics, Inc. (NASDAQ:OBLN) on Monday, October 31 with “Buy” rating. The rating was initiated by Stifel Nicolaus on Monday, October 31 with “Buy”.

Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The company has market cap of $73.26 million. It offers the Obalon balloon system designed to provide weight loss in obese patients. It currently has negative earnings.

More notable recent Obalon Therapeutics, Inc. (NASDAQ:OBLN) news were published by: Seekingalpha.com which released: “Obalon Therapeutics’ (OBLN) CEO Andrew Rasdal on Q3 2017 Results – Earnings …” on November 03, 2017, also Globenewswire.com with their article: “Obalon Announces Termination of Public Offering of Common Stock” published on January 23, 2018, Businesswire.com published: “Bragar Eagel & Squire, PC is Investigating Obalon Therapeutics, Inc. (OBLN) on …” on January 23, 2018. More interesting news about Obalon Therapeutics, Inc. (NASDAQ:OBLN) were released by: Seekingalpha.com and their article: “Obalon Therapeutics’ (OBLN) CEO Andy Rasdal on Q1 2017 Results – Earnings Call …” published on May 10, 2017 as well as Digitaljournal.com‘s news article titled: “Robbins Arroyo LLP Is Investigating the Officers and Directors of Obalon …” with publication date: February 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: